Antje M Richter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6889429/publications.pdf

Version: 2024-02-01

566801 752256 20 654 15 20 citations h-index g-index papers 20 20 20 981 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	The ZAR1 protein in cancer; from epigenetic silencing to functional characterisation and epigenetic therapy of tumour suppressors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188417.	3.3	6
2	Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. Cancers, 2020, 12, 3528.	1.7	13
3	RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice. Oncogene, 2020, 39, 3114-3127.	2.6	12
4	RASSF10 Is a TGF \hat{I}^2 -Target That Regulates ASPP2 and E-Cadherin Expression and Acts as Tumor Suppressor That Is Epigenetically Downregulated in Advanced Cancer. Cancers, 2019, 11, 1976.	1.7	8
5	Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function. Clinical Epigenetics, 2019, 11, 182.	1.8	15
6	ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer. Clinical Epigenetics, 2017, 9, 60.	1.8	15
7	Impact of Natural Compounds on DNA Methylation Levels of the Tumor Suppressor Gene RASSF1A in Cancer. International Journal of Molecular Sciences, 2017, 18, 2160.	1.8	36
8	The tumor suppressor RASSF1A induces the YAP1 target gene <i>ANKRD1</i> that is epigenetically inactivated in human cancers and inhibits tumor growth. Oncotarget, 2017, 8, 88437-88452.	0.8	32
9	Aberrant Promoter Methylation of the Tumour Suppressor RASSF10 and Its Growth Inhibitory Function in Breast Cancer. Cancers, 2016, 8, 26.	1.7	25
10	The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms. BMC Cancer, 2016, 16, 49.	1.1	19
11	Promoter Methylation Status of Ras-Association Domain Family Member in Pheochromocytoma. Frontiers in Endocrinology, 2015, 6, 21.	1.5	17
12	Claudin11 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin, but Uncommon in Nevus Cell Nevi. Cancers, 2015, 7, 1233-1243.	1.7	20
13	ABCB4 is frequently epigenetically silenced in human cancers and inhibits tumor growth. Scientific Reports, 2014, 4, 6899.	1.6	24
14	The apoptosis associated tyrosine kinase gene is frequently hypermethylated in human cancer and is regulated by epigenetic mechanisms. Genes and Cancer, 2014, 5, 365-374.	0.6	25
15	Aberrant Promoter Hypermethylation of RASSF Family Members in Merkel Cell Carcinoma. Cancers, 2013, 5, 1566-1576.	1.7	19
16	RASSF10 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin but Uncommon in Nevus Cell Nevi. Journal of Investigative Dermatology, 2012, 132, 687-694.	0.3	42
17	Epigenetic Silencing of Erythropoietin in Human Cancers. Genes and Cancer, 2011, 2, 65-73.	0.6	31
18	Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Molecular Cancer, 2010, 9, 264.	7.9	50

ANTJE M RICHTER

#	Article	IF	CITATIONS
19	Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics, 2009, 4, 571-576.	1.3	48
20	The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1796, 114-128.	3.3	197